Sweden· SE-20110517000029
Pioglitazone Teva Pharma 15 mg Tablett
A pioglitazone product, registered in Sweden by Teva B.V.. The same ATC class is registered in 18 of our 19 countries.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
Where it is registered
Pioglitazone is registered in 18 of 19 countries.
Countries holding a registration under ATC A10BG03 (pioglitazone), each read from that country’s own register.
- This record: Sweden, from Swedish Medical Products Agency (Sweden)
- 10 of them publish a price we can compare per daily dose
Pioglitazone · ATC A10BG03
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pioglitazone costs, country by country.
Normalised to the WHO defined daily dose (30 mg), the median price runs from $0.11 in United States to $1.64 in Switzerland — a ×14 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Pioglitazone · price per daily dose (30 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.64
- ES Spain$1.22
- IT Italy$0.81
- US United States$0.11 (acquisition cost)
The record
At a glance
Swedish Medical Products Agency (Sweden)- Manufacturer
- Teva B.V.
- Country
- Sweden (SE)
- ATC code
- A10BG03
- ATC class
- Pioglitazone
- Defined daily dose
- 30 mg, O
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- August 27, 2026
Packs & prices · 1
- se_varunummer20110517000029
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
732 interactions on record for pioglitazone.
Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pioglitazone · interactions on record
732 records
- 11 severe
- 302 moderate
- 63 minor
- 355 info
Most severe, free to view
- ClopidogrelB01AC04severe
- GemfibrozilC10AB04severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A10BG03
Pioglitazone, as other registers publish it.
- CanadaACH-PIOGLITAZONEACCORD HEALTHCARE INC
- CanadaACH-PIOGLITAZONEACCORD HEALTHCARE INC
- CanadaACH-PIOGLITAZONEACCORD HEALTHCARE INC
- CanadaACT PIOGLITAZONETEVA CANADA LIMITED
- CanadaACT PIOGLITAZONETEVA CANADA LIMITED
- CanadaACT PIOGLITAZONETEVA CANADA LIMITED
- FinlandActosOrifarm Oy
- DenmarkActosTakeda Pharma A/S
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ff558b7f-83f8-4a6a-a388-a18077d60f50 GET /v1/drugs/ff558b7f-83f8-4a6a-a388-a18077d60f50?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"EPAR",
"EMA"
],
"se_npl_id": "20110517000029",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20110517000029",
"product_doc_link": "https://www.ema.europa.eu/sv/documents/product-information/pioglitazone-teva-pharma-epar-product-information_sv.pdf"
}See everything about pioglitazone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.